Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096810 | 1.00 | CHRM2 (0.32) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL18812568 | 1.00 | CHRM2 (0.32) | CHRM2CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL18813791 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL18813854 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL18813789 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL18813790 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL18699920 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL18812567 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL20094090 | 0.80 | PIK3CD (0.31) | — | |
| SCHEMBL17852580 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190194150-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| WO-2018072707-A1 | AROMATIC ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL APPLICATIONS THEREOF | 保诺科技（北京）有限公司 | 2018-04-26 | — | — | WO | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| EP-1521125-B1 | Electrophotographic photoconductor, electrophotographic method, electrophotographic apparatus, process cartridge for electrophotographic apparatus and azo compound | RICOH CO LTD (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM3 4853/4885CHRM4 4830/4885 |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM3 4853/4885CHRM4 4830/4885 |
| US-20190194150-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | CHRM2 4845/4885CHRM3 4220/4885CHRM4 4359/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CHRM2 4607/4885CHRM3 3753/4885CHRM4 4618/4885 |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM3 4853/4885CHRM4 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.